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Ampullary Adenomas 
 
Tumors of the papilla of Vater are rare, with a 
prevalence of 0.04%±0.12% reported in 
autopsy studies. They may occur as sporadic 
lesions or in patients with familial 
adenomatous polyposis. Histologically, the 
malignant transformation of benign adenomas 
to carcinomas has been documented. The 
reported frequency of malignancy in an 
adenoma of the papillae ranges from 26 to 
65%. Adenomatous residual foci, as well as 
areas of moderate to severe dysplasia, have 
also been found in up to 90% of resection 
specimens of carcinoma of the major papilla. 
Based on these observations, adenomas of the 
major or the minor papilla are thought to 
exhibit the same adenoma-carcinoma 
sequence as adenomas of the colon [1]. 
For these reasons, complete removal of these 
lesions is mandatory, but the treatment of 
choice remains controversial. 
Surgery represents the traditional option, 
including pancreaticoduodenectomy which 
has a peri-operative mortality rate ranging 
from 2 to 9% and a very significant 
postoperative complication rate (up to 41% in 
a large series) [2] and duodenotomy with 
local excision; the latter is certainly less 
invasive, but it is associated with local 
recurrence. 
Thus, because of low morbidity and mortality, 
endoscopic treatment has gained increasing 
consensus as a treatment of first choice, even 
if the difficult anatomic location of these 
lesions makes resection a much more 
complex procedure as compared to a 
polypectomy in the colon [3]; furthermore, 
subsequent surgery in operable patients is not 
precluded by previous endoscopic resection 
[4]. 
 
Preoperative Evaluation: How to Choose 
the Treatment? 
 
On the basis of endoscopic appearance alone, 
ampullary adenomas cannot always be 
distinguished from ampullary carcinomas or 
non-adenomatous polyps (carcinoid tumors, 
gangliocytic paragangliomas, etc.). 
Thus, a definitive tissue diagnosis is a 
prerequisite for appropriate management, but 
forceps biopsies in a certain percentage of 
cases do not allow a correct histological 
determination of the lesion. 
To overcome this difficulty some authors 
propose a more extensive diagnostic and 
therapeutic use of ampullectomy instead of a 
forceps biopsy: the quality of the histological 
specimens may be better, the pathological 
diagnosis more accurate and the need for new 
biopsies significantly reduced [5]. 
Another important focus of staging is 
represented by the evaluation of the biliary 
and/or pancreatic intraductal growth which 
has been considered to be a contraindication 
for endoscopic therapy by many authors; 
therefore, endoscopic retrograde 
cholangiopancreatography (ERCP) with a 
side-viewing duodenoscope is required in all 
patients in order to obtain both a 
cholangiogram and a pancreatogram before 
resection to demonstrate a potential 
intraductal extension of the tumor. 
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In addition to ERCP, endoscopic ultrasound 
(EUS) and/or intraductal ultrasound (IDUS) 
can be performed to provide more detailed 
and accurate information on the extent of the 
papillary lesion, such as the size and the 
echogenicity of the tumor, layered structures 
of the duodenal wall and regional lymph node 
status. The data reported in the literature have 
revealed that linear EUS is superior to helical 
CT in the preoperative assessment of tumor 
size, detection of regional nodal metastases 
and detection of major vascular invasion in 
patients with periampullary malignancies. 
Linear array EUS has improved the 
preoperative local staging of periampullary 
malignancies when cases were compared by 
findings at surgery (Tables 1 and 2). 
There is no consensus as to which ampullary 
adenomas should be kept under surveillance 
and which lesions should be removed 
endoscopically or surgically. 
Several authors have advocated that 
endoscopic resection should only be 
performed in patients without evidence of 
invasive cancer. For other authors, endoscopic 
resection is not controindicated even in the 
case of evidence of a high-grade dysplasia. 
Table 3 shows the criteria for the endoscopic 
resectability most frequently reported in the 
literature. It should be noted that there is a 
notable variability in inclusion criteria. Some 
authors exclude lesions greater than 4-4.5 cm 
for local resection whereas others include 
them; application of piecemeal resection, 
when appropriate, has contributed to 
increasing the size of the lesions treated: for 
example, tumors up to 7 cm in diameter have 
been successfully resected. 
However, the crucial point is represented by 
the histological staging of ampullary 
adenomas. Generally, local excision is an 
accepted curative treatment for an adenoma 
with high-grade intraepithelial neoplasia/tumor 
in situ (HGIN/Tis). In T1 cancer, defined 
according to the TNM classification as a 
tumor limited to the ampulla or the sphincter 
of Oddi, there is lymphovascular invasion or 
lymph-node metastases and ductal 
involvement in 10-50% and 20-40% of cases, 
respectively. Therefore, in this case, there is a 
greater chance of incomplete resection and/or 
cancer recurrence; similar to the management 
of colorectal adenomas, endoscopic ampul-
lectomy may be curative for T1 cancer 
without lymphovascular invasion if 
histological examination of the entire resected 
specimen confirms complete removal [6]. 
Furthemore, another impotant focus regards 
the intraductal growth, which can be found in 
both Tis and T1 adenomas and also in 
adenomas with low grade displasia. 
Bohnacker et al. [7] suggest that surgery is 
recommended in the case of intraductal 
growth in Tis and T1; in adenomas with low 
grade dysplasia, if the intraductal growth is 
smaller than 1 cm, there is still a choice of 
endoscopic resection. In any case, surgery 
remains the only choice in the case of 
incomplete removal and if malignancy is 
clearly present [3]. 
Table 1. Comparison between EUS and CT for 
periampullary tumor staging (tumor size and lymph 
node metastases) in 48 patients. 
 Tumor 
size 
 Lymphnode 
metastases 
 EUS CT  EUS CT 
Sensitivity 100% 68%  61% 33% 
Specificity 75% 50%  100% 92% 
Accuracy 98% 67%  84% 68% 
Modified from [23] 
Table 2. Comparison between EUS and CT for periampullary tumor staging (vascular invasion). 
Sensitivity  Specificity  Accuracy  No. of 
patients EUS CT  EUS CT  EUS CT 
Rösch et al., 1991 [24] 102 91% 36%  97% 85%  - - 
Sugiyama et al., 1997 [25] 91 91% 64%  92% 79%  92% 75% 
Gress et al., 1999 [26] 81 - -  - -  93% 62% 
Rivadeneira et al., 2003 [23] 48 - -  - -  100% 45% 
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Figure 1 shows a possible flow-chart for 
orienting the therapeutic steps. 
In the presence of familial adenomatous 
polyposis, some recommendations must be 
made. These patients very often develop 
adenomas in the second part of the 
duodenum, including the papilla of Vater, but 
pancreaticoduodenectomy is not always 
mandatory.  
The risk of cancer is assessed by the 
Spigelman classification (Table 4) [8]. About 
10-30% of patients with familial adenomatous 
polyposis develop a Spigelman stage IV 
duodenal adenomatosis; mutations down-
stream from codon 1051 seem to be 
associated with severe periampullary lesions 
[9]. These patients have a cumulative cancer 
risk of 30-40% and a prophylactic 
pancreaticoduodenectomy should therefore be 
considered. 
Endoscopic treatment can be performed in the 
remaining stages (eventually associated with 
chemoprevention in stages II-III) with a close 
endoscopic follow-up after the complete 
excision of the ampullary lesion [3, 9]. 
 
Techniques of Endoscopic Snare 
Papillectomy 
 
Techniques for the endoscopic removal of 
ampullary adenomas remain non-
standardized, probably due to the relatively 
small number of procedures of this type It is 
important to remember that the term 
‘‘ampullectomy’’ refers to the removal of the 
entire ampulla of Vater and it is a surgical 
term for procedures which require surgical 
reimplantation of the distal common bile duct 
and pancreatic duct within the duodenal wall. 
Technically, when endoscopic resections of 
lesions at the major papilla are performed, 
only tissue from the papilla can be removed 
endoscopically, and thus the term 
‘‘papillectomy’’ is more appropriate than the 
term ‘‘ampullectomy’’ although the two are 
often used interchangeably in the literature. 
The duodenal papillae (major and minor) 
Figure 1. Flow-chart of therapeutic steps. 
HGIN: high-grade intraepithelial neoplasia 
LGIN: low-grade intraepithelial neoplasia 
TIS: tumor in situ 
Table 3. Criteria of endoscopic resectability. 
 Size No malignant 
aspect a 
Positive 
lifting sign 
Benign 
histology at 
biopsies b 
No invasion of 
the biliary and 
pancreatic ducts 
Carcinoma
in situ c 
Binmoeller et al., 1993 [16] <4 cm Yes - Yes - Excluded 
Desilets et al., 2001[10] <4 cm Yes Yes - Yes Excluded 
Norton et al., 2002 [12] Indifferent - - - - Included 
Cheng et al., 2004 [1] <4.5cm Yes - Yes - Excluded 
a Regular margins, no ulceration, soft consistency 
b Minimum 6 biopsies 
c No invasion of muscolaris mucosae 
Table 4. Spiegelman classification [8]. 
 Score 
 1 2 3 
No. of polyps 1-4 5-20 >20 
Size (mm) 1-4 5-10 >10 
Histology Tubulous Tubulovillous Villous 
Dysplasia Mild Moderate Severe 
Stage 0: Score 0 
Stage I: Score 1-4 
Stage II: Score 5-6 
Stage III: Score 7-8 
Stage IV: Score 9-12 
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should be inspected using a side-viewing 
endoscope (duodenoscope), as papillary 
pathology is easily missed with forward-
viewing instruments. A submucosal injection 
prior to the resection is recommended by 
some authors [7, 10], but not routinely 
required (similar to that used before 
performing endoscopic mucosal resection for 
colorectal polyps). The failure of a lesion to 
manifest a ‘‘lift sign’’ is associated with 
malignancy and is considered by many 
authors as a contraindication to attempts at 
complete endoscopic resection. 
Fluids injected into the submucosa have 
included saline solution, epinephrine, 
methylene blue, and viscous materials such as 
hydroxypropyl methylcellulose. The volume 
of the fluid injected are not standardized. 
Moreover, injection, particularly of 
epinephrine, may also decrease the risk of 
bleeding during snare ampullectomy [11]. 
On the contrary, some investigators do not 
recommend submucosal injection because it 
can be difficult to capture the lesion with a 
snare and because submucosal injection may 
blur the margin of the tumor and does not 
elevate the bile duct which runs through the 
duodenal wall. 
Endoscopic papillectomy is performed by use 
of endoscopic snares and electrocautery. In 
most reports, standard ‘‘braided’’ 
polypectomy snares have been used, although 
fine-wire snares specifically designed for 
ampullary resection are available. There is no 
evidence documenting the advantage of one 
type of snare over another. 
If the lesion can be completely ensnared, en 
bloc resection can be performed. En bloc 
resection has the advantage of potentially 
shortening the procedure time, requiring less 
electrocautery, and providing a complete 
tissue sample for pathologic evaluation. 
However, piecemeal resection is often 
performed for lesions larger than 2 cm, in 
cases where an attempt at en bloc resection 
has left visible neoplastic tissue in place or to 
minimize the risk of perforations. Piecemeal 
resection may produce electrocautery-related 
injury to tissue fragments sent for pathologic 
analysis. Larger lesions may require multiple 
endoscopic procedures in order to be 
completely removed. Most published series 
have reported using a combination of en bloc 
and piecemeal resection techniques as the 
types of lesions treated were of mixed size 
and structure. There is no consensus as to 
which type of current should be used during 
endoscopic papillectomy. Both pure cutting 
current, blended current or endocut have been 
used and neither has been proven to be 
superior over the other at this time. Power 
settings are also not standardized [1, 10, 12]. 
After papillectomy (en bloc or piece-meal) 
Nd:YAG laser or argon plasma coagulation 
could be used to remove remaining 
adenomatous tissue [13]. Pancreatic or biliary 
sphincterotomy may assist in providing 
pancreaticobiliary drainage after papillectomy 
and may simplify attempts to access the 
common bile duct and pancreatic duct for 
stent placement. They may also help in post-
procedure endoscopic surveillance. 
Several studies have shown that placement of 
a prophylactic pancreatic duct stent reduces 
the risk of post-ERCP pancreatitis [10, 14, 
15], minimizing the risk of stenosis of the 
pancreatic duct orifice and may also allow 
safer use of adjunctive coagulative therapies, 
but this theory is unproven. Others advocate 
pancreatic stent placement only if the 
pancreatic duct does not drain after 
papillectomy [16, 17]. 
In the study of Zádorová et al. [17], the rate 
of pancreatitis in patients who underwent 
papillectomy with and without a pancreatic-
duct stent was 0% and 20%, respectively. A 
multicenter study [12] found post-procedure 
pancreatitis to be more common in patients 
who did not have a pancreatic stent placed 
(17% vs. 3.3%), although the difference was 
not statistically significant. In the study of 
Cheng et al. [1], prophylactic placement of a 
pancreatic stent was associated with a lower 
rate of post-ESP pancreatitis (9.6% vs. 25%; 
P=0.33) [18, 19]. 
However, the only prospective, randomized, 
controlled trial to evaluate the role of 
prophylactic pancreatic duct stenting for the 
reduction of post-ERCP pancreatitis after 
endoscopic papillectomy showed a 
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statistically significant decrease in the rate of 
postprocedure pancreatitis in the stent group 
[20]. On the basis of these data, prophylactic 
pancreatic duct stenting during papillectomy 
is recommended to reduce the risk of 
postprocedural pancreatitis whereas .there is 
no data as to how long the duct should be 
stented [20]. 
Although there is extensive discussion about 
pancreatic duct stent placement, there is also a 
question regarding the need for biliary 
drainage after a papillectomy. There have 
been occasional reports of biliary stent 
placement after endoscopic papillectomy [1, 
16], with the diameter of the stent used 
varying from 7F to 10F. Nasobiliary drainage 
could be a valid alternative to a stent 
permitting X-ray control of the drainage of 
the bile duct for a few days after the 
procedure without the need for a new 
endosocopic examination. 
Theoretically, cholangitis can occur after 
endoscopic papillectomy by the same 
pathogenetic mechanism as post-papillectomy 
pancreatitis and, in effect, a case of 
cholangitis after endoscopic papillectomy has 
been reported [21]. In any case prophylactic 
biliary stenting to reduce the risk of 
postprocedural cholangitis has not been 
widely performed and cannot be uniformly 
recommended at this time unless there is 
concern about inadequate biliary drainage 
after a papillectomy. 
 
Complications 
 
Endoscopic removal of ampullary adenomas 
is considered a ‘‘high-risk’’ procedure for 
complications, with a morbidity and mortality 
of 23% (range 10-58%) and 0.4% (range 0-
7%), respectively. Complication rates 
reported by large, tertiary care referral centers 
and experienced therapeutic endoscopists are 
as follows: pancreatitis 8 to 15%, perforation 
0 to 4%, bleeding 2 to 13%, cholangitis 0 to 
2% and papillary stenosis 0 to 8%. Therefore, 
a period of postprocedure inpatient 
observation should be considered for the 
detection and treatment of any immediate or 
slightly delayed complications, especially 
after extensive removal and treatment of large 
lesions, in patients with comorbid medical 
illnesses, those who do not have ready access 
to medical care and those without support 
measures. 
Most cases of bleeding reported in the 
literature refer to procedural bleeding and 
have been managed endoscopically during the 
same procedure. The consensus of opinion is 
that these should not be regarded as 
complications. Delayed bleeding has been 
reported in approximately 3% of cases and 
was usually also managed conservatively or 
by endoscopic re-intervention. Only a few 
cases of severe pancreatitis requiring 
prolonged hospitalization have been reported. 
Surgery is rarely required [20]. 
Late complications include the development 
of pancreatic or biliary stenosis; these 
complications seem more frequent in patients 
without pancreatic duct stents placed after 
papillectomy (15.4%) with respect to patients 
who received pancreatic stents (1.1%) [15]. 
Some authors [10, 22] suggest that it is 
possible to reduce the complication rate with 
routine biliary and pancreatic sphincterotomy, 
placement of a pancreatic stent before 
resection, submucosal injection of 
epinephrine and piece-meal resection in larger 
lesions. 
 
Results of Endoscopic Treatment 
 
Results of endoscopic treatment of ampulla 
tumors reported in the literature are shown in 
Table 5. It should be noted that, in the study 
of Catalano et al., the success rate was 
associated with older age (54.7 vs. 46.6 years; 
P=0.08), smaller lesions (21.1 vs. 29.7 mm; 
P<0.0001) and sporadic lesions (63 of 72 vs. 
20 of 31; P=0.02) [15]. 
Bohnacker et al. [7] focalized the results on 
the presence or absence of intraductal tumor 
growth; in their report carried out on 106 
patients studied for a median follow-up of 43 
months, the authors found that endoscopic 
resection was curative in 83% of patients 
without intraductal growth and in 46% of 
patients with intraductal growth (P<0.001), 
concluding that endoscopic ampullectomy is 
safe and effective, and may be feasible in 
cases of intraductal growths less than 1 cm. 
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In the study of Cheng et al., [1], six patients 
(out of the 55 patients enrolled) had 
intraductal growths: two underwent surgical 
resection, considered to be the treatment of 
choice; four patients (poor candidates for 
surgery or refusing surgery) underwent 
intraductal therapy with Nd:YAG laser (2 
patients) or endoscopic snare resection (2 
patients). In these four patients, the 
intraductal tumor was eliminated although 
one of the patients who had laser therapy had 
a recurrence at a mean follow-up of 12 
months. Therefore, the authors suggest that, in 
patients not eligible for surgery, intraductal 
adenoma can be eradicated also without 
considering the cut-off indicated by 
Bohnacker [7] (tumor extending less than 1 
cm from the biliary orifice). 
Recurrence rate reported in the literature 
ranges from 0 to 33%; predisposing factors 
seem referable to larger size and genetic 
predisposition; the application of adjuvant 
thermal ablation can reduce the recurrence 
rate [15] even if this technique is also 
associated with an increasing morbidity [13]. 
However, very often the recurrent tissue is 
limited in size, histologically benign, without 
intraductal growth and thus easily amenable 
to endoscopic techniques [1]. 
 
Surveillance after Endoscopic Treatment 
 
An optimal program of surveillance after 
complete excision of ampullary tumor is not 
standardized. Based on the experiences 
reported in the literature, it seems desirable - 
once complete excision is achieved - to 
perform ERCP with biopsies of the ampullary 
region every 6 months for 2 years. 
In cases where there is no recurrence after 2 
years, endoscopic surveillance should be 
carried out more frequently in patients with 
familial adenomatous polyposis than in 
patients with sporadic lesions because of the 
high prevalence of duodenal adenomas and 
the risk of periampullary cancer. Therefore, 
patients with familial adenomatous polyposis 
should undergo endoscopy at 3 year intervals 
whereas the remaining patients should repeat 
endoscopy only in presence of symptoms [3, 
7, 15]. 
 
Conclusions 
 
Endoscopic treatment of adenomas of the 
major duodenal papilla is a safe, well-
tolerated alternative to surgical therapy. In 
expert hands, complications are rare and 
surgery is generally not required. The eligible 
patients must be selected carefully and an 
Table 5. Results of endoscopic treatment. 
Author No. of 
patients 
Histology Recurrence Mean follow-up
(months) 
Mean No. 
of sessions 
Morbidity Mortality
Desilets et al., 2001 [10] 13 12 adenomas
1 HGIN/Tis 
0% 19  3.2 8% 0% 
Saurin et al., 2003 [13] a 24 10 LGDs 
14 HGIN/Tis
6.2% 66  3 29.1% 0% 
Catalano et al., 2004 [15] 103 83 LGDs 
14 HGIN/Tis
6 T1 (surgery)
20% 36  - 9.7% 0% 
Cheng et al., 2004 [1] 55 38 LGDs 
7 HGIN/Tis
5 T1s 
5 other b 
33% 30  1.3 14.6% 0% 
Soon Man et al., 2007 [27] 16 10 HGIN/Tis
6 T1s 
0% 18 (HGIN/Tis)
29 (T1) 
- - 0% 
a Endoscopic destruction methods only (argon plasma coagulation, Nd:YAG laser) 
b Carcinoid tumor (No. 2); normal histology (No. 2); gastric heterotopia (No. 1) 
LGD: low-grade dysplasia 
HGIN/Tis: high-grade intraepithelial neoplasia/tumor in situ 
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endoscopic follow-up must be assured. A 
longer follow-up is needed to determine the 
true recurrence rate (33% in the literature) and 
the long-term results of endoscopic re-
treatment [1]. 
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